paediatrics Brussels 17

Non-infants (PNET5-MB and HR-MB): Next biology steps

Next biomarkers / refine risk- stratification:

•

New subgroups Level of evidence?

• • •

When?

New strategies for VHR patients

•

Identify targeted therapeutics:

•

• Link to pre-clinical / early-phase initiatives • HR-MB window